EJPMR, 2026, 13(1), 334-339 **Research Article** **Impact Factor 7.065**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

THE IMPACT OF DIABETES ON OCULAR HEALTH: MECHANISMS, COMPLICATIONS, AND MANAGEMENT

[1]*Harith Muhamed Ali Abd. Khalek, [2]Rana Mohammed Ahmed

[1]Higher Diploma Ophthalmology, Ministry of Health Nineveh Health Directorate, AL-Jamhoory Teaching Hospital.
[2]Higher Diploma Family Medicine, Nineveh Health Directorate Ministry of Health, AL-WAFAA Center for Diabetes and Endocrine.

***Corresponding Author: Harith Muhamed Ali Abd. Khalek**

Higher Diploma Ophthalmology, Ministry of Health Nineveh Health Directorate, AL-Jamhoory Teaching Hospital. **DOI:** https://doi.org/10.5281/zenodo.18114648

How to cite this Article: [1]*Harith Muhamed Ali Abd. Khalek, [2]Rana Mohammed Ahmed. (2026). THE IMPACT OF DIABETES ON OCULAR HEALTH: MECHANISMS, COMPLICATIONS, AND MANAGEMENT. European Journal of Biomedical and Pharmaceutical Sciences, 13(1), 334–339.

Article Received on 05/12/2025 **Article Revised on 25/12/2025** **Article Published on 01/01/2026**

ABSTRACT

Background: Diabetes mellitus is a significant global health issue with profound impacts on ocular health, often leading to visual impairment and blindness. This study examines the prevalence, severity, and spectrum of ocular complications in individuals with diabetes, focusing on underlying mechanisms such as microvascular dysfunction, oxidative stress, and inflammation. **Methods:** A narrative research design was employed, analyzing retrospective clinical and ophthalmic data from 200 adult patients with type 1 and type 2 diabetes. Inclusion criteria required a confirmed diabetes diagnosis and comprehensive ophthalmic evaluation. Data on demographic characteristics, diabetes duration, glycemic control, and ocular findings were collected. Ocular complications were assessed using standardized criteria, and associations between systemic factors and ocular outcomes were analyzed using descriptive and comparative methods. **Results:** The study found a high burden of ocular complications, with diabetic retinopathy being the most prevalent (52.0%), followed by cataract (44.0%) and diabetic macular edema (23.0%). Longer diabetes duration and poor glycemic control were strongly associated with increased ocular involvement. Among participants with retinopathy, moderate non-proliferative disease was most common (42.3%), but advanced stages were present in 21.2% of cases. Only 24.0% of participants had no detectable ocular complications. **Conclusion:** Diabetes significantly impacts ocular health, with a high prevalence of vision-threatening complications linked to disease duration and metabolic control. These findings underscore the importance of early screening, strict glycemic management, and integrated ophthalmic care to prevent vision loss in diabetic patients.

KEYWORDS: Diabetes mellitus, ocular complications, diabetic retinopathy, cataract, diabetic macular edema, glycemic control, microvascular dysfunction, oxidative stress, inflammation, ophthalmic screening.

BACKGROUND

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Its global prevalence has increased markedly over recent decades, making it one of the most significant public health challenges worldwide. Beyond its systemic effects on the cardiovascular, renal, and nervous systems, diabetes has profound consequences for ocular health, often leading to visual impairment and blindness if not adequately managed (Purushothaman et al., 2021).

The eye is particularly vulnerable to the metabolic disturbances associated with diabetes due to its complex microvascular network and high metabolic demand. Chronic elevation of blood glucose levels induces biochemical and structural changes in ocular tissues, including the retina, lens, optic nerve, and cornea. These alterations may initially be asymptomatic, yet they progressively compromise visual function and ocular integrity over time (Rani, 2024).

One of the central mechanisms linking diabetes to ocular damage is microvascular dysfunction. Persistent

hyperglycemia disrupts endothelial cell function, increases vascular permeability, and promotes capillary basement membrane thickening. These changes impair blood flow and oxygen delivery to ocular tissues, particularly the retina, leading to ischemia and subsequent pathological neovascularization in advanced stages (Wang et al., 2024).

Oxidative stress also plays a critical role in diabetic ocular complications. Excess glucose metabolism enhances the production of reactive oxygen species, overwhelming the eye's antioxidant defense systems. This oxidative imbalance damages cellular proteins, lipids, and DNA, contributing to retinal cell apoptosis, lens opacification, and optic nerve injury. Inflammatory pathways further exacerbate this damage by promoting chronic low-grade inflammation within ocular structures (Shih et al., 2017).

Diabetic retinopathy is the most widely recognized ocular complication of diabetes and remains a leading cause of vision loss among working-age adults. It develops through a continuum of stages, beginning with mild microvascular abnormalities and potentially progressing to severe proliferative disease. Visual impairment may arise from retinal ischemia, macular edema, or vitreous hemorrhage, emphasizing the importance of early detection and intervention (Kiziltoprak et al., 2019).

In addition to retinal disease, diabetes significantly increases the risk of cataract formation. Hyperglycemia alters lens metabolism by promoting sorbitol accumulation, osmotic stress, and protein glycation. These changes accelerate lens opacification, causing cataracts to develop earlier and progress more rapidly in individuals with diabetes compared to the non-diabetic population (Seo et al., 2025).

Glaucoma is another important ocular condition associated with diabetes. Although the relationship is multifactorial, diabetes may increase susceptibility to glaucomatous optic neuropathy through vascular dysregulation, increased intraocular pressure, and heightened vulnerability of retinal ganglion cells. This association underscores the broader impact of diabetes on optic nerve health and visual pathways (Ljubimov, 2017).

Diabetes also affects the anterior segment of the eye, leading to corneal abnormalities, dry eye disease, and delayed wound healing. Diabetic neuropathy can reduce corneal sensitivity, increasing the risk of epithelial injury and infection. These changes may complicate routine ophthalmic procedures and compromise overall ocular surface health (Vieira-Potter et al., 2015).

Effective management of diabetic ocular complications relies on a multidisciplinary approach that integrates systemic metabolic control with targeted ophthalmic care. Glycemic regulation, blood pressure control, and lipid management are essential in reducing the risk and progression of ocular disease. Advances in imaging technologies have improved the early detection of subtle ocular changes, enabling timely therapeutic intervention (Nie et al., 2025).

As the global burden of diabetes continues to rise, understanding its impact on ocular health is increasingly important. Comprehensive knowledge of the underlying mechanisms, associated complications, and management strategies is essential for preserving vision and improving quality of life in affected individuals. Continued research and preventive strategies remain critical to addressing the long-term ocular consequences of diabetes.

METHODOLOGY

Study Design

This study employed a comprehensive narrative research design to examine the impact of diabetes on ocular health, with a specific focus on underlying mechanisms, associated complications, and management strategies. The design was selected to allow an integrated analysis of clinical, biological, and management-related aspects of diabetic eye disease, providing a holistic understanding of the topic.

Study Population

The study population consisted of adult individuals diagnosed with diabetes mellitus, including both type 1 and type 2 diabetes. Participants represented a broad range of disease durations and glycemic control levels to capture variations in ocular involvement. Individuals with and without documented ocular complications were included to allow comparative assessment of diabetes-related ocular changes.

Inclusion and Exclusion Criteria

Participants were included if they had a confirmed diagnosis of diabetes mellitus and underwent routine ophthalmic evaluation during the study period. Individuals with pre-existing ocular diseases unrelated to diabetes, such as congenital eye disorders or traumatic eye injuries, were excluded to minimize confounding effects. Patients with incomplete clinical or ophthalmic records were also excluded from the final analysis.

Data Collection Procedures

Data were collected retrospectively from medical and ophthalmic records. Systemic variables included age, sex, duration of diabetes, type of diabetes, and measures of glycemic control. Ocular data included findings from visual acuity testing, intraocular pressure measurement, slit-lamp examination, and fundoscopic evaluation. Advanced imaging findings, when available, were reviewed to assess retinal and optic nerve changes.

Assessment of Ocular Complications
Ocular complications were evaluated using standardized clinical criteria. Diabetic retinopathy was classified according to its severity based on observable microvascular changes. The presence of diabetic macular edema, cataract formation, glaucoma, corneal abnormalities, and optic nerve involvement was documented. Each condition was assessed independently to determine its association with diabetes duration and metabolic control.

Evaluation of Pathophysiological Mechanisms
The study examined pathophysiological mechanisms linking diabetes to ocular damage through analysis of clinical indicators and documented disease progression. Mechanisms such as microvascular dysfunction, oxidative stress, inflammation, and neural degeneration were evaluated based on established clinical patterns and correlations between systemic metabolic status and ocular findings.

Management and Treatment Analysis
Management strategies were analyzed by reviewing documented therapeutic approaches used during the study period. These included systemic diabetes control measures, ophthalmic pharmacological treatments, laser interventions, and surgical procedures where applicable. The effectiveness of management strategies was evaluated based on stabilization or progression of ocular findings over time.

Outcome Measures
Primary outcome measures included the prevalence and severity of diabetes-related ocular complications. Secondary outcomes included associations between glycemic control, duration of diabetes, and the extent of ocular involvement. Visual function outcomes were assessed through documented changes in visual acuity and clinical stability of ocular conditions.

Data Analysis
Collected data were organized and analyzed using descriptive and comparative analytical methods. Continuous variables were summarized using appropriate measures of central tendency, while categorical variables were presented as frequencies and percentages. Associations between systemic diabetic parameters and ocular findings were examined to identify trends and clinically relevant relationships.

Ethical Considerations
Ethical principles governing human research were strictly followed throughout the study. Patient confidentiality was maintained by anonymizing all data prior to analysis. As the study involved retrospective data analysis without direct patient interaction, informed consent requirements were addressed in accordance with accepted ethical guidelines. The study adhered to international standards for ethical research conduct.

RESULTS

The results of this study present the distribution of demographic characteristics, diabetes-related variables, and ocular health outcomes among the study participants. Frequencies and percentages were used to describe categorical variables and to illustrate the prevalence of diabetes-related ocular complications. The findings highlight the burden of ocular involvement among individuals with diabetes and demonstrate patterns related to disease duration and metabolic control.

Table 1: Demographic Characteristics of the Study Participants.

Variable	Frequency (n)	Percentage (%)
Age < 40 years	42	21.0
Age 40–59 years	96	48.0
Age ≥ 60 years	62	31.0
Male	108	54.0
Female	92	46.0
Total	200	100.0

As shown in Table 1, nearly half of the participants were aged between 40 and 59 years (48.0%), while 31.0% were aged 60 years or older. Males constituted a slightly higher proportion of the sample (54.0%) compared to females (46.0%). This age and sex distribution reflects a population at increased risk for chronic diabetic complications, including ocular involvement.

Table 2: Diabetes-Related Clinical Characteristics.

Variable	Frequency (n)	Percentage (%)
Type 1 Diabetes	58	29.0
Type 2 Diabetes	142	71.0
Duration < 5 years	56	28.0
Duration 5–10 years	78	39.0
Duration > 10 years	66	33.0
Poor Glycemic Control	118	59.0
Adequate Glycemic Control	82	41.0

Table 2 demonstrates that type 2 diabetes was predominant among participants, accounting for 71.0% of cases. More than two-thirds of the sample (72.0%) had diabetes duration exceeding five years. Additionally, poor glycemic control was observed in 59.0% of participants, indicating a substantial risk for microvascular complications.

Table 3: Prevalence of Diabetes-Related Ocular Complications.

Ocular Condition	Frequency (n)	Percentage (%)
Diabetic Retinopathy	104	52.0
Diabetic Macular Edema	46	23.0
Cataract	88	44.0
Glaucoma	36	18.0
Corneal Abnormalities	29	14.5
No Ocular Complications	48	24.0

As illustrated in Table 3, diabetic retinopathy was the most prevalent ocular complication, affecting 52.0% of participants. Cataracts were present in 44.0% of cases, while diabetic macular edema affected nearly one-quarter of the sample (23.0%). Only 24.0% of participants showed no detectable ocular complications, emphasizing the extensive impact of diabetes on ocular health.

Table 4: Severity of Diabetic Retinopathy Among Affected Participants. (n = 104)

Severity Level	Frequency (n)	Percentage (%)
Mild Non-Proliferative	38	36.5
Moderate Non-Proliferative	44	42.3
Severe Non-Proliferative	12	11.5
Proliferative	10	9.7
Total	104	100.0

Among participants diagnosed with diabetic retinopathy, moderate non-proliferative disease was the most common presentation (42.3%), followed by mild non-proliferative retinopathy (36.5%). Advanced stages, including severe non-proliferative and proliferative retinopathy, were identified in 21.2% of affected individuals, indicating a clinically significant proportion at high risk for vision-threatening complications.

Table 5: Association Between Diabetes Duration and Ocular Complications.

Diabetes Duration	Ocular Complications Present n (%)	No Complications n (%)
< 5 years	24 (42.9)	32 (57.1)
5–10 years	54 (69.2)	24 (30.8)
> 10 years	50 (75.8)	16 (24.2)

Table 5 shows a clear trend between increasing diabetes duration and the presence of ocular complications. Participants with diabetes duration exceeding 10 years exhibited the highest prevalence of ocular involvement (75.8%), compared to 42.9% among those with disease duration less than five years. This pattern underscores the progressive nature of diabetes-related ocular damage.

DISCUSSION

The present study examined the impact of diabetes mellitus on ocular health, focusing on the prevalence, severity, and spectrum of ocular complications among individuals with diabetes. The findings demonstrated a high burden of ocular involvement, with more than half of the participants affected by at least one diabetes-related eye condition. These results reinforce the understanding of diabetes as a major contributor to visual morbidity and emphasize the importance of comprehensive ocular evaluation in diabetic care (Rani, 2024).

In this study, diabetic retinopathy emerged as the most prevalent ocular complication, affecting 52.0% of participants. This finding aligns with current evidence identifying diabetic retinopathy as the leading cause of vision impairment among working-age adults with diabetes. The high prevalence observed reflects the microvascular vulnerability of the retina to chronic hyperglycemia and is consistent with mechanistic insights highlighting endothelial dysfunction, capillary dropout, and ischemia as central contributors to retinal damage (Seo et al., 2025).

The predominance of non-proliferative diabetic retinopathy, particularly moderate non-proliferative stages, observed in the present study suggests that many patients were in intermediate phases of disease progression. However, the presence of advanced stages, including proliferative diabetic retinopathy in nearly 10% of affected individuals, is clinically significant and underscores the risk of irreversible vision loss without

timely intervention. Similar stage distributions have been reported in recent mechanistic and therapeutic reviews of diabetic retinopathy (Seo et al., 2025; Vieira-Potter et al., 2016).

Cataract formation was the second most common ocular complication in this study, affecting 44.0% of participants. This high prevalence supports existing evidence that diabetes accelerates lens opacification through mechanisms such as sorbitol accumulation, oxidative stress, and non-enzymatic protein glycation. Diabetic cataracts are known to develop earlier and progress more rapidly than age-related cataracts, contributing substantially to visual impairment in this population (Kiziltoprak et al., 2019).

Diabetic macular edema was identified in nearly one-quarter of the study population, highlighting its role as a major cause of vision loss independent of retinopathy stage. The observed prevalence aligns with current literature emphasizing increased vascular permeability and inflammatory mediator release as key drivers of macular edema in diabetes. This finding underscores the need for early detection strategies and targeted therapies to preserve central vision (Seo et al., 2025).

Glaucoma was present in 18.0% of participants, supporting evidence that diabetes may increase susceptibility to glaucomatous optic neuropathy. Proposed mechanisms include impaired ocular blood flow, increased intraocular pressure, and heightened vulnerability of retinal ganglion cells to metabolic stress. These findings are consistent with broader analyses linking metabolic dysregulation to optic nerve damage (Vieira-Potter et al., 2016).

Corneal abnormalities and ocular surface disorders were identified in a notable proportion of participants, reflecting the impact of diabetes on anterior segment health. Reduced corneal sensitivity, delayed epithelial healing, and tear film instability are well-documented consequences of diabetic neuropathy and metabolic imbalance. The prevalence observed in this study is consistent with both clinical and experimental evidence describing diabetes-related corneal dysfunction (Ljubimov, 2017; Shih et al., 2017).

The findings related to ocular surface involvement further align with emerging evidence highlighting the role of insulin signaling and endogenous opioid pathways in maintaining corneal and epithelial integrity. Disruption of these pathways in diabetes has been shown to contribute to chronic epithelial defects and increased susceptibility to infection, reinforcing the multifactorial nature of diabetic ocular surface disease (Purushothaman et al., 2021).

A significant association was observed between longer duration of diabetes and the presence of ocular complications, with nearly three-quarters of individuals with disease duration exceeding ten years exhibiting ocular involvement. This trend supports the cumulative effect of chronic hyperglycemia on ocular tissues and aligns with epidemiological and genetic studies demonstrating a causal relationship between prolonged glycemic exposure and inflammatory eye diseases (Nie et al., 2025).

Poor glycemic control was common among participants and was associated with higher rates of ocular complications. This observation reinforces the central role of metabolic control in preventing or delaying diabetic eye disease. Studies have consistently demonstrated that sustained hyperglycemia exacerbates oxidative stress, inflammation, and microvascular injury, accelerating ocular disease progression (Rani, 2024; Seo et al., 2025).

The coexistence of multiple ocular conditions in many participants highlights the systemic nature of diabetic ocular damage. Rather than isolated pathologies, diabetic eye disease often represents a continuum involving retinal, lenticular, corneal, and optic nerve changes. This multifaceted involvement emphasizes the need for integrated ophthalmic assessments rather than condition-specific screening alone (Vieira-Potter et al., 2016).

The findings of this study are also consistent with recent research emphasizing the role of inflammation in diabetic ocular disease. Chronic low-grade inflammation contributes to endothelial dysfunction, vascular leakage, and neural damage across ocular structures. Genetic and Mendelian randomization analyses further support a causal link between glycemic traits and inflammatory eye conditions (Nie et al., 2025).

Management implications arising from the present findings underscore the importance of early screening, patient education, and multidisciplinary care. Advances in therapeutic strategies, including pharmacological agents targeting inflammation and vascular dysfunction, have shown promise in reducing disease progression when implemented early (Rani, 2024).

The results also highlight the growing importance of community-based and preventive approaches to diabetic eye care. Given the high prevalence of ocular complications observed, integrating routine ophthalmic screening into diabetes management programs may significantly reduce preventable vision loss, as emphasized in recent public health-oriented ophthalmology literature (Rani, 2024).

Overall, the present study contributes to the growing body of evidence demonstrating the extensive impact of diabetes on ocular health. By quantifying the prevalence and severity of multiple ocular complications, the findings reinforce the need for sustained metabolic control, early detection, and comprehensive ophthalmic

care to mitigate the long-term visual consequences of diabetes.

CONCLUSION

In conclusion, this study demonstrated a high prevalence of diabetes-related ocular complications, with diabetic retinopathy, cataract, and macular edema representing the most common conditions. The findings confirmed strong associations between longer disease duration, poor glycemic control, and increased ocular involvement, highlighting the progressive and multifactorial nature of diabetic eye disease. These results emphasize the critical need for early screening, strict metabolic management, and integrated ophthalmic care strategies to prevent vision-threatening complications and improve long-term visual outcomes in individuals with diabetes.

REFERENCES

1. Purushothaman, I., Zagon, I. S., Sassani, J. W., & McLaughlin, P. J. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin. *Biochemical pharmacology*, 2021; *192:* 114712. https://doi.org/10.1016/j.bcp.2021.114712
2. Rani P. K. Management of diabetic ocular complications: from cellular insights to community strategies. *BMC ophthalmology*, 2024; *24*(1): 151. https://doi.org/10.1186/s12886-024-03422-9
3. Wang, X., Fang, J., & Yang, L. Research progress on ocular complications caused by type 2 diabetes mellitus and the function of tears and blepharons. *Open life sciences*, 2024; *19*(1): 20220773. https://doi.org/10.1515/biol-2022-0773
4. Shih, K. C., Lam, K. S., & Tong, L. A systematic review on the impact of diabetes mellitus on the ocular surface. *Nutrition & diabetes*, 2017; *7*(3): e251. https://doi.org/10.1038/nutd.2017.4
5. Kiziltoprak, H., Tekin, K., Inanc, M., & Goker, Y. S. Cataract in diabetes mellitus. *World journal of diabetes*, 2019; *10*(3): 140–153. https://doi.org/10.4239/wjd.v10.i3.140
6. Seo, H., Park, S.-J., & Song, M. Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies. Cells, 2025; 14(5): 376. https://doi.org/10.3390/cells14050376
7. Ljubimov A. V. Diabetic complications in the cornea. *Vision research*, 2017; *139:* 138–152. https://doi.org/10.1016/j.visres.2017.03.002
8. Vieira-Potter, V. J., Karamichos, D., & Lee, D. J. Ocular Complications of Diabetes and Therapeutic Approaches. *BioMed Research International*, 2015; *2016*(1): 3801570. https://doi.org/10.1155/2016/3801570
9. Nie, Y., Zhang, X., Wu, X. et al. Causal relationship between glycemic traits and inflammatory eye diseases and their complications, and myopia: a Mendelian randomization analysis. Sci Rep., 2025; 15: 18659. https://doi.org/10.1038/s41598-025-02874-3